Animas Corporation's CGM system received FDA approval

The FDA has approved the Animas Corporation’s Animas Vibe insulin pump and continuous glucose monitoring system for managing insulin in adults aged ≥18 years with diabetes, according to a company press release.

“For many people who are insulin dependent, diabetes is a demanding disease that can require day-to-day and hour-by-hour management,” Brian Levy, MD, chief medical officer of the Animas Corporation, said in the release. “We are pleased to now offer people with diabetes in the United States a solution with [continuous glucose monitoring (CGM)] technology that provides the ability to make more informed decisions to manage their disease, which can ultimately improve blood glucose control.”

The system, which features Dexcom G4 Platinum sensing technology, provides patients with their latest glucose readings every 5 minutes as well as trend information.

The system can be worn for up to 7 days, is waterproof up to 12 feet for 24 hours, is the first system with a high-contrast color screen, and has customizable alerts to warn of high and low glucose levels.

“We are excited to bring Animas Vibe to the United States, which expands our insulin portfolio and delivers on our promise to provide a range of solutions that help patients perform at their very best,” Ty Lee, vice president of Johnson & Johnson Diabetes Solutions, said in the release.